Mitsubishi Tanabe lands '$940m' revenue boost after Novartis win

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Mitsubishi Tanabe lands '$940m' revenue boost after Novartis win

NovartisCOVER.jpg
Credit: Taljat / Adobe Stock

Paul Hastings led Mitsubishi Tanabe to victory over Novartis at the International Chamber of Commerce

Japanese pharma company Mitsubishi Tanabe has secured an arbitration victory against Novartis at the International Chamber of Commerce, a case related to blockbuster multiple sclerosis drug Gilenya (fingolimod).

According to Mitsubishi Tanabe, a subsidiary of Mitsubishi Chemical Group, the award will see its revenue increase by around $940 million.

The tribunal, which issued the decision on Monday, February 13, denied Novartis’s claims that provisions of a licence controlling royalties that it had to pay to Mitsubishi Tanabe in the US, EU and other jurisdictions were invalid.

Although Mitsubishi had received royalties from Novartis’s Gilenya, which used the Japanese company's patent rights and know-how, it hadn’t recognised those royalties as revenue. This was due to International Financial Reporting Standards 15, which sets out how to report information about revenue and cash flows from contracts with customers.

However, as a result of the ICC's decision, Mitsubishi can now recognise these royalties as revenue.

In a filing with Japan’s Financial Accounting Standards Foundation on Thursday, February 16, Mitsubishi said it was revising its revenue forecast for this quarter by ¥126 billion ($938.4 million) in light of the arbitration win.

The filing said: “The royalties which have not been recognised as revenue … during the arbitration proceedings will all be recognised as revenue in the fourth quarter of the fiscal year ending March 31 2023.”

Mitsubishi also received ¥3 billion in arbitration-related costs from Novartis.

The Swiss pharma company had filed an application for an arbitration against Mitsubishi Tanabe in 2019.

Paul Hastings advised Mitsubishi Tanabe.

more from across site and SHARED ros bottom lb

More from across our site

Value-added services give in-house counsel the satisfaction that they are getting more value for money, while law firms get the opportunity to win more work
A team at Boies Schiller Flexner is advising shoe company Kizik and parent company HandsFree Labs in the dispute
Nokia’s latest enforcement actions against Geely and Transsion joining Via LA’s AAC pool were also among the top talking points
Benjamin Kelly, the firm’s fifth IP partner hire in a little over one year, has experience in patent and trade secret disputes involving complex technologies
Half-year Talent Tracker data shows Pierson Ferdinand was among the most prolific hirers in the US, while in Europe, there has been a notable UPC swing
Exclusive data reveals in-house counsel want external legal advisers to build better client relationships and add value beyond routine work
Brett Sandford acted for Perplexity AI, which fended off the threat of a preliminary injunction to launch an AI-powered web browser
Stephen Yang joins us for our ‘Five minutes with’ series to explain why his role requires him to wear many hats
The complaint follows a declaratory ruling issued by the England and Wales High Court last month that said Samsung is entitled to an interim licence
Tobias Hahn explains how the firm's multi-jurisdictional setup enabled it to secure an injunction on behalf of Fujifilm relating to defendant Kodak’s non-UPC activity
Gift this article